American Society of Hirudotherapy

Idiopathic Intracranial Hypertension (Highly Investigational)

Highly investigational. Acetazolamide, weight loss, and (for vision-threatening cases) CSF shunting or optic nerve sheath fenestration remain primary; no clinical study of leech therapy for intracranial pressure was identified.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for idiopathic intracranial hypertension. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (highly investigational). No clinical study of leech therapy for this condition was identified in our literature search. Evidence-based first-line management is weight loss (which is often disease-modifying), acetazolamide (in the Idiopathic Intracranial Hypertension Treatment Trial, adding it to a weight-reduction diet gave a modest further improvement in visual field, of borderline statistical significance, and an improvement in papilledema grade in patients with mild visual loss), topiramate as alternative, and for sight-threatening or refractory disease optic nerve sheath fenestration, CSF shunting (VP or LP shunt), or venous sinus stenting. Vision must be monitored urgently — papilledema with field loss is the principal threat.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Vision-threatening disease — any delay in proven therapy risks permanent blindness
  • No mechanistic plausibility for leech effect on CSF dynamics
Who should not consider this
  • Patients with papilledema and visual-field loss (need urgent neuro-ophthalmologic and possibly surgical intervention)
  • Patients who have not been started on acetazolamide and a weight-management plan
  • Patients with secondary causes of intracranial hypertension that have not been worked up
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
What to ask your clinician
  • Have I been started on acetazolamide at therapeutic doses?
  • Has my weight management plan been optimized — including consideration of bariatric surgery if BMI is high?
  • What is my current visual field status, and how often will it be checked?
  • Has venous sinus stenosis been excluded by MRV?
  • If vision is at risk, should I have CSF shunting or optic nerve sheath fenestration?
  • What is the published evidence base for leeches in IIH (likely none)?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Any new vision change — blurring, blackout, peripheral field loss, double vision
  • Severe worsening of headache or new neurologic symptoms
  • Pulsatile tinnitus worsening abruptly

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for IIH — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace acetazolamide, weight management, or surgical CSF diversion for sight-threatening disease.
  • It has not been shown to affect CSF production or absorption, and the proposed venous-outflow mechanism is speculative.
  • It does not prevent permanent vision loss, which is the principal risk in IIH.
  • It has no RCT or case-series evidence in this condition that our literature search could identify.

Clinical Profile

Category
Neurological
ICD-10
G93.2
Safety tier
High

Evidence Summary

Idiopathic intracranial hypertension (IIH) is elevated intracranial pressure without identifiable cause, predominantly affecting women of childbearing age with obesity, presenting with headache, papilledema, and visual disturbance. Evidence-based management includes weight reduction and acetazolamide (the IIH Treatment Trial, in patients with mild visual loss) and, for vision-threatening disease, surgical intervention (CSF diversion, optic nerve sheath fenestration, venous sinus stenting). No clinical study of leech therapy in idiopathic intracranial hypertension was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or Russian-language sources (searched October 2026). Russian hirudotherapy texts describe leech use in children with hydrocephalic encephalopathy or with vertebrobasilar venous congestion and raised intracranial pressure (Yakovleva 2001; Stroganova 1999, as cited in Baskova and Isakhanyan 2004); that is a different population, the accounts are descriptive (Stroganova's mentions a control group without giving its results), and they cannot be extrapolated to IIH. The proposed mechanism via venous outflow modulation is highly speculative. Application carries no demonstrated benefit and standard risks. Visual outcome is the priority and must drive treatment decisions.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Acute or progressive visual deterioration (urgent neuro-ophthalmology referral)
  • Severe papilledema requiring acute surgical intervention
  • Venous sinus thrombosis (this is a different diagnosis; needs anticoagulation)
  • Pregnancy (IIH frequently coincides; different management)
  • Patient not on evidence-based therapy

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.